# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Edap TMS (NASDAQ:EDAP) with a Buy and maintains $19 price ...
Robotic HIFU therapy continues to maintain an excellent safety profile, confirming positive safety data from prior Phase 1 and ...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Edap TMS (NASDAQ:EDAP) with a Buy and maintains $19 price ...
Final results demonstrate a significantly higher salvage treatment free survival rate (STFS) at 30 months of 89.6% in the HIFU-...
- SEC Filing
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Edap TMS (NASDAQ:EDAP) with a Buy and raises the price targ...
Edap TMS (NASDAQ:EDAP) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.05) by...